HOYNG ROKH MONEGIER regularly advises clients on intellectual property and regulatory issues in the rapidly evolving field of biotechnology, branded biologics and biosimilars. Our team is comprised of highly experienced IP attorneys with an in-depth understanding of the legal, technical, regulatory and business issues that arise in this complex field and how they impact our clients.
Effective patent and regulatory protection in the biotech and biologics field requires an integrated approach, which takes into account various aspects. We have a proven regulatory and litigation track record in biotech and biologics and have experience dealing with technologies such as antibody therapies, biocompatible materials, biologically produced or genetically modified food ingredients and chemicals, protein therapies, and genetically modified crops. Our experience in and outside the courtroom and across all relevant practice areas allows us to determine and follow up on unique patent and regulatory strategies for each individual case, thereby offering our clients maximum leverage.
